Updates are available Correction dated 2018-12-04
Click to view Correction: https://doi.org/10.1007/s40262-018-0726-6
-
Authors
Qi, Yulan
McKeever, Kathleen
Taylor, Julie
Haller, Christine
Song, Wenjie
Jones, Simon A.
Shi, Jack
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct01856218 at ClinicalTrials.govnct02418455 at ClinicalTrials.govDocuments that mention this clinical trial
Pharmacokinetic and Pharmacodynamic Modeling to Optimize the Dose of Vestronidase Alfa, an Enzyme Replacement Therapy for Treatment of Patients with Mucopolysaccharidosis Type VII: Results from Three Trials
https://doi.org/10.1007/s40262-018-0721-y
nct02230566 at ClinicalTrials.govDocuments that mention this clinical trial
Pharmacokinetic and Pharmacodynamic Modeling to Optimize the Dose of Vestronidase Alfa, an Enzyme Replacement Therapy for Treatment of Patients with Mucopolysaccharidosis Type VII: Results from Three Trials
https://doi.org/10.1007/s40262-018-0721-y
Documents that mention this clinical trial
The multi-domain responder index: a novel analysis tool to capture a broader assessment of clinical benefit in heterogeneous complex rare diseases
https://doi.org/10.1186/s13023-021-01805-5
Pharmacokinetic and Pharmacodynamic Modeling to Optimize the Dose of Vestronidase Alfa, an Enzyme Replacement Therapy for Treatment of Patients with Mucopolysaccharidosis Type VII: Results from Three Trials
https://doi.org/10.1007/s40262-018-0721-y
-
Funding
Funding for this research was provided by:
Ultragenyx Pharmaceutical Inc.
- License Information
-
More Information
Article History
First Online: 23 November 2018
Compliance with Ethical Standards
:
: These studies were funded by Ultragenyx Pharmaceutical Inc.
: Study protocols for all procedures performed in studies involving human participants were reviewed and approved by Institutional Review Boards at each investigational site, and conducted in accordance with principles in the Declaration of Helsinki and the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Good Clinical Practice guidelines.
: Yulan Qi, Wenjie Song, and Christine Haller were employees of Ultragenyx Pharmaceutical Inc. at the time of the study. Kathleen McKeever, Julie Taylor, and Jack Shi are employees of Ultragenyx Pharmaceutical Inc. Simon A. Jones has been an investigator and consultant for Ultragenyx Pharmaceutical Inc.
: Each participant or his/her legally authorized representative provided written informed consent before entering the study, in compliance with the applicable local regulations.
